37 results about "Epitope vaccine" patented technology

The invention relates to the technical field of biology, in particular to a swine transmissible gastroenteritis virus epitope vaccine and a preparation method and application thereof, the amino acid sequence of FliCS.T-TGEV-S fusion protein is shown as SEQ ID NO.3, and the nucleotide sequence of the FliCS.T-TGEV-S fusion protein is shown as SEQ ID NO.4. The fusion protein FliCS.T-TGEV-S prepared by the invention is used as an epitope vaccine based on dominant antigen epitopes of TGEV, and combines advanced means such as immunodominant epitopes, a fusion protein technology and genetic engineering, so that the specificity and the protection effect of the vaccine are enhanced. The vaccine not only can induce high-level antibody response and effectively inhibit TGEV infection, but also has relatively high safety and stability. Compared with a traditional vaccine, the vaccine has remarkable advantages in the aspects of production cost, immune efficacy, protection durability and the like, and a feasible TGE prevention and control scheme is provided for the pig industry.

The invention discloses a type 2 GAstV capsid protein monoclonal antibody and an antigen epitope peptide of the type 2 GAstV capsid protein monoclonal antibody. The monoclonal antibody is prepared by immunizing a mouse with capsid protein GAstV Cap of the type 2 goose astrovirus as an antigen, and is named as 1F1; the monoclonal antibody 1F1 comprises a heavy chain variable region and a light chain variable region, and the amino acid sequences of the heavy chain variable region and the light chain variable region are sequentially shown as SEQ ID No.3 and SEQ ID No.5. In order to determine the B cell antigen epitope of the screened monoclonal antibody, the invention also constructs a GAstV Cap truncated fusion protein, and the antigen recognition epitope is determined through indirect ELISA and Western blotting tests, so that screening is carried out step by step until the shortest linear epitope recognized by the monoclonal antibody is determined, and the amino acid sequence of the shortest linear epitope is shown as SEQ ID No.10. Therefore, the monoclonal antibody and the antigen epitope of the monoclonal antibody can be applied to research on structures and functions of GAstV capsid proteins and preparation of serological diagnostic tools and epitope vaccines.

In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against SARS-CoV-2. In certain embodiments the immunogenic nanoparticles comprise mRNA multi-epitope vaccines that can be used in combination with or independent of other covid-19 vaccines (e.g., the spike protein mRNA vaccine(s)) to invoke a strong CD8+ or CD4+ T-cell as well as neutralizing antibody producing B-cell responses. In certain embodiments this vaccine is based on the rational combination of well-conserved T- and B-cell epitopes identified COVID-19 and viral variants.

The invention provides an avian adenovirus D11 type tandem multi-epitope vaccine, and belongs to the technical field of veterinary vaccines. According to the invention, an amino acid sequence of fiber protein of the fowl adenovirus D11 type is analyzed, 10 potential B cell epitopes are screened out, 10 antigen epitopes are artificially synthesized to prepare the vaccine, and six antigen epitopes with high neutralizing antibody titer are screened out by immunizing chicken. Flexible peptides are designed among the screened six antigen epitopes for connection, and a series multi-epitope antigen is designed. The oil emulsion vaccine is prepared by expressing tandem multi-epitope antigen protein through recombinant escherichia coli, purifying through a nickel column, and emulsifying with a mineral oil adjuvant. All test chickens immunized by the series multi-epitope vaccine in an over-dose manner have no abnormities in spirit, ingestion and water drinking, injection parts have no red and swollen reactions, and the vaccine is good in safety. The series multi-epitope vaccine has a good immune effect, can enable the immunized chicken to generate a neutralizing antibody to achieve challenge protection, and can block the detoxification of the challenge chicken.

In order to seek an echinococcosis antigen which has good immunogenicity and can activate an organism to generate an effective immune response against echinococcosis granulosa infection, the invention provides an echinococcosis multi-epitope antigen and application thereof in preparation of a vaccine for preventing echinococcosis. The multi-epitope antigen is formed by sequentially connecting CTLA-4-lgV, a T cell epitope of EgA31, a T cell epitope of EgG1Y162, a B cell epitope of EgA31 and a B cell epitope of EgG1Y162 in series, the multi-epitope antigen can be specifically combined with serum of a cystic echinococcosis patient, a mouse immunized by a vaccine can generate specific B cell response and generate specific cellular immunity and an antibody, and the multi-epitope antigen has good immunogenicity.

The invention relates to an epitope polypeptide of cryptosporidium parvum targeting CD4 + T cells and application of the epitope polypeptide. The amino acid sequence of the epitope polypeptide is shown as SEQ ID NO.1; the epitope polypeptide is a combined long epitope polypeptide of cryptosporidium parvum Gp40 / 15 protein, Gp900 protein and CSL protein; the epitope polypeptide can be applied to a vaccine for preventing or treating cryptosporidiosis parvum, and after a mouse is immunized by the vaccine, not only can CD8 + T cell immune response of the mouse be obviously stimulated, but also stronger CD4 + T cell response is induced to be generated, and the mouse can be induced to generate multifunctional T cells related to an immune protection effect; the levels of IFN-gamma, TNF-alpha and IL-2 generated by multifunctional T cells induced by a long polypeptide immune group have extremely significant differences (P is less than 0.01) compared with various negative controls, which indicates that the long polypeptide epitope vaccine has corresponding biological immunological activity and becomes a novel cryptosporidium parvum infection resistant T cell epitope vaccine or an immunodominance T cell epitope-based mRNA vaccine.

The present invention provides a tandem multi-epitope vaccine against fowl adenovirus type D11, belonging to the technical field of veterinary vaccines. The present invention analyzes the amino acid sequence of the fiber protein of fowl adenovirus type D11, screens out 10 potential B-cell epitopes, artificially synthesizes 10 antigenic epitopes to prepare a vaccine and immunizes chickens to screen out 6 antigenic epitopes with relatively high neutralizing antibody titers. Flexible peptides are designed to be linked between the 6 screened antigenic epitopes to design a tandem multi-epitope antigen. The tandem multi-epitope antigen protein is expressed by recombinant Escherichia coli, emulsified with a mineral oil adjuvant after purification by a nickel column to prepare an oil emulsion vaccine. All the experimental chickens immunized with the tandem multi-epitope vaccine at an overdose showed no abnormalities in spirit, feeding and drinking, and there was no swelling reaction at the injection site, indicating good vaccine safety. The tandem multi-epitope vaccine has a good immunization effect, can enable the immunized chickens to produce neutralizing antibodies, achieve protection against challenge, and can block the excretion of challenged chickens.

The application discloses a SARS-CoV-2 epitope type vaccine multi-epitope combination and application, and belongs to the technical field of coronavirus vaccine research and development.The first aspect of the application relates to a fusion protein, which comprises in sequence: (a) a SARS-CoV-2 spike protein receptor binding domain or a functional fragment thereof; (b) a T cell epitope domain, comprising: a CTL epitope cluster, the CTL epitope cluster comprising at least one CD8+ T cell epitope polypeptide selected from SEQ ID NO: 1-15; and (c) an immunoglobulin Fc domain.The application adopts a tandem strategy of immunodominant epitopes + conserved epitopes, predicts high-affinity T cell epitopes by computational biology methods, evaluates the HLA restriction in different populations, introduces a flexible linker peptide for optimization design, evaluates the immune effect difference of different combinations through in vitro and animal models, analyzes the synergistic or competitive relationship between epitopes, and optimizes the vaccine design.Through systematic comparison of the immunological effect difference of different epitope combinations and the adaptability to various vaccine platforms, the application establishes an optimized safe, efficient, broad-spectrum and long-acting multi-epitope vaccine design strategy, and has significant application value and important transformation value.

This invention discloses an epitope peptide of the key SRCR5 domain of porcine reproductive and respiratory syndrome virus (PRRSV) CD163, an epitope peptide vaccine, and its applications. The epitope vaccine of this invention exhibits good safety, without safety issues such as virulence reversion, viremia, or recombination with other PRRSV strains. It also demonstrates good immunogenicity; 14 days after secondary immunization, it can induce pigs to produce specific antibodies against the CD163 SRCR5-FP14 epitope with a maximum agglutination titer of 1:16. Immunized pigs can resist challenge from the highly pathogenic PRRSV JAX1 strain. Since all PRRSV subtypes rely on interaction with the CD163 receptor to infect susceptible host cells, and the CD163 molecule is conserved, the epitope vaccine blocking PRRSV infection also provides broad-spectrum protection against multiple subtypes without affecting pig production performance. This novel epitope vaccine has broad potential applications in PRRS prevention and control.

The invention relates to an HIV (Human Immunodeficiency Virus) nanoparticle vaccine. According to the invention, through a structural biology strategy and a nanoparticle vaccine platform, immunogens with stable conformations are respectively designed for MPER and CD4bs, and are respectively displayed through virus-like particles (VLP), and finally, a combined double-epitope vaccine (Cocktail) is constructed. The immune effect of the vaccine in a mouse model finds that the vaccine can induce MPER and CD4bs double-target specific antibodies and stimulate the neutralizing activity on multi-subtype HIV pseudoviruses, and the broad spectrum is good.

According to the invention, dominant antigen epitopes of main outer membrane proteins OspA, OspB and OspC of borrelia burgdorferi are screened out, and a multi-epitope fusion vaccine containing the epitopes and application are constructed. The vaccine design not only improves the specificity and immunogenicity of the antigen. Compared with a traditional antigen epitope screening and construction strategy, the method has the advantages that the cycle is shortened, the cost is reduced, meanwhile, the limitations of many and complex antigens, large toxic and side effects and the like of a traditional vaccine are overcome, the operation process is simplified, the method is more suitable for large-scale epitope screening, popularization and application, and a new thought and strategy are provided for research and development of borrelia burgdorferi vaccines.

Compositions of peptides modified to enhance HLA binding or T cell recognition while preserving reactivity to target neoepitopes enhance the activation of neoantigen-specific T cells. The method of use involves treating cancer by administering one or more of these peptides, which are produced by computer modeling.

The invention provides a multi-epitope vaccine antigen based on BCG, which comprises a recombinant epitope polypeptide sequence formed by sequentially connecting a CD8 + T cell epitope (CTL) polypeptide sequence, a CD4 + T cell epitope (HTL) polypeptide sequence, a B cell epitope (LBEs) polypeptide sequence and a B cell conformational epitope (CBEs) polypeptide sequence in series, the multi-epitope vaccine antigen provided by the invention can have good recognition and binding effects with an immune related receptor, is an effective immune antigen target, has a relatively strong immune effect, has a remarkable effect on humoral immune level and cellular immune level induced in a mouse body, and is higher than BCG immune level.

The invention discloses an avian leukosis tetravalent epitope mRNA vaccine and application, and belongs to the technical field of immunology and biology. According to epidemic strains of A, B, J and K subgroup avian leukosis viruses in recent 10 years, epitopes with relatively high antigenicity and conservative property in surface proteins (gp85 gene coding) are screened and connected in series, so that immune escape caused by self gene mutation of the avian leukosis viruses is avoided, the protection range is wider, and the kit has a good application prospect. And a molecular adjuvant is also added into an mRNA vaccine sequence to enhance the cellular immunity of the vaccine, so that the problem of low antigenicity of other vaccines is solved. Compared with purification investment, the vaccine has the advantages that the capital cost is saved by more than 50%, the consumption of time, manpower and material resources is greatly reduced, and the vaccine has a good application prospect.

The invention belongs to the technical field of microbial immunity and DNA vaccines, and particularly relates to a preferred epitope peptide of a Crimean-Congo hemorrhagic fever virus envelope glycoprotein C terminal (CCHFV Gc), a tandem multi-epitope vaccine, an expression vector and application. The preferable epitope peptide is composed of any one amino acid sequence as shown in SEQ ID NO.1-SEQ ID NO.21, and the preferable epitope peptide has high affinity, strong immunogenicity and interspecific amp; and an intraspecific conservative preferred epitope. Preferably epitopes are connected in series through a linker to synthesize a series multi-epitope vaccine, the series multi-epitope vaccine enters cells to be expressed to form recombinant protein, then T lymphocytes are activated, and cellular immune response is induced. The in-vivo vaccine evaluation of animals is carried out by using the tandem multi-epitope vaccine, and it is proved that the vaccine can effectively induce anti-CCHFV specific cellular immune response and the application safety in BALB / c mice. The invention is helpful for understanding the immunobiology of CCHFV Gc and perfecting the epitope vaccine design for the virus in the future.

The invention discloses a streptococcus pneumoniae PsaA protective epitope peptide, a vaccine and a preparation method and application thereof, the nucleotide sequence of the epitope peptide is shown as SEQ ID NO.1, a novel epitope vaccine ZnuA-PsaA-Loop90 (for short, ZPL90) is successfully constructed based on the epitope, after the vaccine is inoculated, an anti-Loop90 antibody can be efficiently induced in a mouse, the mouse can be effectively protected from being infected with streptococcus pneumoniae, and the streptococcus pneumoniae PsaA protective epitope peptide can be used for preparing the vaccine. Good application prospects are realized.

The invention discloses a staphylococcus aureus MntC protective epitope peptide, an epitope vaccine as well as a preparation method and application of the staphylococcus aureus MntC protective epitope peptide and the epitope vaccine, the protective B cell epitope peptide Loop101 of a staphylococcus aureus MntC antigen is obtained, the novel epitope vaccine MntC101 is successfully constructed based on the epitope, after the vaccine is inoculated, an anti-Loop101 antibody can be efficiently induced in SPF and staphylococcus aureus pre-infected mice, and the staphylococcus aureus MntC protective epitope peptide and the novel epitope vaccine MntC101 can be used for preparing the staphylococcus aureus MntC protective epitope peptide. SPF and pre-infected mice can be effectively protected from being infected with staphylococcus aureus, and the method has a good application prospect.

The invention discloses a gB, gH / gL and K8.1 multi-epitope DNA (deoxyribonucleic acid) vaccine for preventing KSHV (Kaposi's sarcoma associated herpes virus), and relates to the technical field of vaccines, in particular to a gB, gH / gL and K8.1 multi-epitope DNA vaccine for preventing KSHV infection, which is delivered by adopting a nano-carrier beta-CD-PEI, and simultaneously delivers a sulfo-modified small-fragment nucleic acid adjuvant, so that the KSHV infection can be effectively prevented and treated. The multi-epitope DNA vaccine mainly comprises four plasmids with His tags, the four plasmids are pcDNA3.1 (+)-gB-his, pcDNA3.1 (+)-K8.1-his, pcDNA3.1 (+)-gH-his and pcDNA3.1 (+)-gL-his, the four plasmids are combined on beta-CD-PEI through electrostatic adsorption, an adjuvant CPGodn1826 is adsorbed, and the KSHV nano multi-epitope DNA vaccine which is stable, high in delivery efficiency and good in immunogenicity is formed. The invention further provides a construction method of the DNA nano vaccine, the nano vaccine is characterized, and the immune effect is verified in a mouse body. Compared with a traditional vaccine, the vaccine provided by the invention has good immunogenicity and safety, and has a relatively great application prospect.

The invention relates to an antigen epitope peptide of an African swine fever virus DP238L protein, belongs to the field of genetic engineering, and determines a T cell antigen epitope of the African swine fever virus DP238L protein for the first time. The acquisition of the antigen epitope lays a foundation for research and development of an African swine fever detection reagent and a kit thereof, preparation of a monoclonal antibody and safe products which are in urgent need of strategic prevention and control and can be used for identifying and diagnosing epitope vaccines and the like by taking the antigen epitope as a material, and not only can huge economic benefits be generated, but also important social benefits are achieved.

This invention relates to the field of biotechnology and provides an antigenic epitope of the parainfluenza virus type 5 F protein, a monoclonal antibody, and its applications. 135 AAILNLKNAIQKTNAAVADVVQA 157 Furthermore, a monoclonal antibody that specifically recognizes this antigenic epitope is provided. The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2. The discovery of this epitope provides a new target for the development of PIV5 diagnostic reagents. Peptide antigens can be designed and synthesized based on this epitope to develop highly specific ELISA diagnostic kits. Simultaneously, this epitope can be used as a candidate epitope for the design of multi-epitope vaccines, providing a new strategy for the prevention and control of PIV5.

The invention discloses a porcine reproductive and respiratory syndrome virus CD163 key SRCR5 structural domain epitope peptide, an epitope peptide vaccine and application. The epitope vaccine is good in safety, has no safety problems of virulence reversion, generation of viremia, recombination with other PRRSV strains and the like, has good immunogenicity, and can induce a pig to generate a specific antibody aiming at the CD163 SRCR5-FP14 epitope with the highest agglutination titer of 1: 16 14 days after secondary immunization, and the immunized pig can resist attack of a highly pathogenic PRRSV JAX1 strain. Each subtype strain of the PRRSV is dependent on interaction with a CD163 receptor so as to infect a host susceptible cell, and CD163 molecules are conservative, so that the epitope vaccine for blocking PRRSV infection also has a broad-spectrum protection effect on various subtype strains, the production performance of pigs is not influenced, and the novel epitope vaccine has a wide potential application prospect in PRRS prevention and control.

The present invention belongs to the field of biotechnology and specifically provides a CMV pp65 epitope vaccine composition and application associated with HLA. The pp65 epitope is one or more combinations of different specific short peptide epitopes, and the encoding nucleotide sequences of the specific short peptides are shown as pp65-EP1, pp65-EP2, pp65-EP3, pp65-EP4, pp65-EP5, pp65-EP6-1, pp65-EP6-2, pp65-EP7, pp65-EP8, or pp65-EP9. The present invention also provides corresponding pp65 epitope amino acid sequences, vectors containing the encoding nucleotide sequences, cells transduced with the amino acid sequences, nucleotide sequences, or vectors, and single or multiple pp65 epitope compositions. These compositions are used to prepare therapeutic vaccines for treating tumors, particularly with good therapeutic effects on brain gliomas and subcutaneous breast cancer tumors.

The present invention belongs to the field of medicine, and particularly relates to a multi-epitope subunit vaccine against all GBS serotypes. The present invention first provides a multi-epitope chimeric protein MVSA against all GBS serotypes, and the amino acid sequence of the multi-epitope chimeric protein MVSA is shown in SEQ ID No: 1. Active immunoprotection tests in mice showed that MVSA could provide 100% protection rate for mice against lethal GBS infection. At the same time, passive immunoprotection tests in mice showed that pre-injection of MVSA antibody could significantly reduce the bacterial load in organs and the levels of pro-inflammatory cytokines in organs of mice after GBS challenge, and provided 100% protection rate for mice against lethal GBS infection. In vitro, MVSA antibody could significantly inhibit the growth of different serotypes of GBS. Therefore, as a multi-epitope vaccine, the protective antibodies produced by MVSA stimulating the body can resist GBS infection, and it has good application prospects.

The invention belongs to the technical field of biological medicines, and particularly relates to a Brucella recombinant multi-epitope vaccine and application thereof. The invention provides a recombinant multi-epitope vaccine protein of Brucella. The vaccine protein is a first vaccine variant rBMEV1 or a second vaccine variant rBMEV2. Results of embodiments prove that the vaccine provided by the invention can excite strong cross immune response aiming at main pathogenic species (such as sheep species, cattle species and pig species) of Brucella. Animal experiments prove that the antibody can induce a high-level and lasting specific antibody, can obviously activate response of CD4 + and CD8 + T cells and corresponding cell factors, and has good safety at the same time. According to the invention, the problems of narrow protection spectrum, dependence on exogenous adjuvants, single immune type and the like of the traditional brucella vaccine are solved, and a new generation of efficient, broad-spectrum and safe candidate vaccine strategy is provided for prevention and control of brucellosis.

The invention provides a preparation method of a novel human / mouse cross-reactive anti-PD-1 candidate vaccine, and belongs to the technical field of candidate vaccine preparation. The candidate vaccine obtained by the preparation method can inhibit combination of PD-1 and PD-L1, can reactivate depleted T cells and break the tumor microenvironment of immunosuppression, and meanwhile, the epitope vaccine is combined with HBc VLPs to stimulate generation of strong T cell immunity, so that generation and development of tumor cells are inhibited in two aspects.

This application relates to an HIV nanoparticle vaccine. The invention utilizes structural biology strategies and a nanoparticle vaccine platform to design stable conformations of immunogens targeting MPER and CD4bs, respectively, and displays them using virus-like particles (VLPs), ultimately constructing a combined dual-epitope vaccine (Cocktail). Immunization in a mouse model revealed that this vaccine can induce dual-target specific antibodies against MPER and CD4bs, and exhibits broad-spectrum neutralizing activity against multiple HIV pseudoviruses.

The present invention provides a nano - material multi - epitope peptide vaccine for preventing animal toxoplasmosis gondii. The vaccine uses PLGA to encapsulate multi - epitope peptides and profilin immune agonists to form nanoparticles. The core composition of the multi - epitope peptide is six dominant peptide segments, namely SAG1 (238‑256) , MIC3 (109‑128) , GRA7 (20‑28) , MIC3 (27‑35) , AS15 peptide, MIC3 (368‑381) . After the multi - epitope peptide is expressed prokaryotically, it is coated with PLGA nano - materials and combined with a profilin immune agonist coated with PLGA nano - materials to form a new vaccine form. Through experiments on a mouse model, it is found that the multi - epitope peptide has good immunogenicity and can effectively stimulate the body to produce humoral immunity and cellular immunity; the combined use of PLGA - rMEP and PLGA - rProfilin can significantly extend the survival time of mice infected with the Toxoplasma gondii RH strain. Therefore, the use of this vaccine can provide partial immune protection and provide an effective candidate vaccine for preventing continued Toxoplasma gondii infection.

The invention discloses a toxoplasma gondii CTL epitope peptide identification method and application. The toxoplasma gondii CTL epitope peptide identification method comprises the following steps: constructing a toxoplasma gondii infection model of an HLA-A * 0201 transgenic mouse; capturing a natural peptide fragment combined with the HLA-A * 0201 molecule from the spleen lymphocyte surface of the infected model mouse through a weak acid elution method; analyzing the captured peptide fragment by adopting a liquid chromatography-tandem mass spectrometry technology, and screening a toxoplasma gondii-sourced specific peptide fragment based on a toxoplasma gondii protein database; through an in-vitro protein renaturation experiment, the binding capacity of the screened candidate peptide fragment and the HLA-A * 0201 molecule is verified; a TAP defect type T2 lymphoblastic cell model is adopted, and the binding stability of the candidate peptide fragment and the HLA-A * 0201 molecule is verified through a fluorescence index. According to the method, through a progressive screening strategy that after natural peptide group screening, a NetMHCpan-4.1 algorithm is adopted for filtering and eliminating host homology, in-vitro pMHC-I renaturation verification and T2 cell binding stability detection are carried out, the clinical transformation value of epitope screening is remarkably improved, and high-confidence candidate molecules are provided for toxoplasma gondii multi-epitope vaccine design.

This invention discloses a method for specifically recognizing antigen epitopes. 16 AQTGYAPV 23 This invention relates to a monoclonal antibody D3-mAb against porcine rotavirus and its applications, belonging to the field of antibody bioengineering technology. The monoclonal antibody D3-mAb specifically binds to the VP8 protein of porcine rotavirus and exhibits neutralizing activity; its amino acid sequence is shown in SEQ ID NO. 8. This invention screened a monoclonal antibody D3 with neutralizing activity against the VP8 protein, and subsequently identified the neutralizing antigenic epitope. 16 AQTGYAPV 23 Recognized by D3-mAb, sequence comparison analysis of currently circulating PoRVA strains revealed that this antigenic epitope is absolutely conserved. Furthermore... 16 AQTGYAPV 23 The epitope, located on the surface of the VP8 protein, interacts with the antibody's variable region via six hydrogen bonds. This invention provides a novel approach for designing novel epitope vaccines and antiviral strategies, and the provided monoclonal antibody holds promise for development into a biotherapeutic agent and diagnostic agent for porcine rotavirus infection.

The present application relates to the field of biotechnology, and particularly relates to a porcine transmissible gastroenteritis virus epitope vaccine, a preparation method and application thereof, and FliC S.T The amino acid sequence of the TGEV-S fusion protein is shown as SEQ ID NO. 3, and the nucleotide sequence is shown as SEQ ID NO. 4. The fusion protein FliCS.T-TGEV-S prepared in the present application is an epitope vaccine based on the dominant antigen epitope of TGEV, which combines the immunodominant epitope, fusion protein technology and advanced genetic engineering methods to enhance the specificity and protection effect of the vaccine. The vaccine can not only induce high-level antibody response and effectively inhibit TGEV infection, but also has high safety and stability. Compared with the traditional vaccine, the vaccine of the present application has significant advantages in production cost, immunization efficacy, protection durability and the like, and provides a feasible TGE prevention and control scheme for the pig industry.